{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:39:46Z","timestamp":1762781986265},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1002\/lary.25976","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T05:20:45Z","timestamp":1460611245000},"page":"2358-2362","source":"Crossref","is-referenced-by-count":22,"title":["Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration"],"prefix":"10.1002","volume":"126","author":[{"given":"Aurore","family":"Picry","sequence":"first","affiliation":[{"name":"Department of Otology and Neurotology; Roger Salengro Hospital; Lille University Hospital; Lille France"},{"name":"Department of Anatomy; \u201cHenri Warembourg\u201d Faculty of Medicine; University of Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas-Xavier","family":"Bonne","sequence":"additional","affiliation":[{"name":"Department of Otology and Neurotology; Roger Salengro Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Aboukais","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery; Roger Salengro Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery; Roger Salengro Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Baroncini","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery; Roger Salengro Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Dubrulle","sequence":"additional","affiliation":[{"name":"Department of Radiology; Claude Huriez Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Otology and Neurotology; Roger Salengro Hospital; Lille University Hospital; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"10.1002\/lary.25976-BIB0001|lary25976-cit-0001","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jmg.29.12.847","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet"},{"key":"10.1002\/lary.25976-BIB0002|lary25976-cit-0002","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"10.1002\/lary.25976-BIB0003|lary25976-cit-0003","first-page":"826","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"75","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1002\/lary.25976-BIB0004|lary25976-cit-0004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1002\/lary.25976-BIB0005|lary25976-cit-0005","first-page":"455","article-title":"Computerized evaluation of tumor volume with MRI. Applications to the surveillance of acoustic neurinoma","volume":"74","author":"Sarazin","year":"1993","journal-title":"J Radiol"},{"key":"10.1002\/lary.25976-BIB0006|lary25976-cit-0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3171\/jns.2002.96.2.0217","article-title":"Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2","volume":"96","author":"Baser","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1002\/lary.25976-BIB0007|lary25976-cit-0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3171\/jns.2002.96.2.0223","article-title":"Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study","volume":"96","author":"Mautner","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1002\/lary.25976-BIB0008|lary25976-cit-0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1002\/lary.25976-BIB0009|lary25976-cit-0009","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"E","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/lary.25976-BIB0010|lary25976-cit-0010","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1227\/NEU.0b013e31828bae28","article-title":"Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results","volume":"72","author":"Peyre","year":"2013","journal-title":"Neurosurgery"},{"key":"10.1002\/lary.25976-BIB0011|lary25976-cit-0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","article-title":"Long-term natural history of neurofibromatosis type 2-associated intracranial tumors","volume":"117","author":"Dirks","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1002\/lary.25976-BIB0012|lary25976-cit-0012","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1227\/01.neu.0000333303.79931.83","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1002\/lary.25976-BIB0013|lary25976-cit-0013","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jmg.2005.031302","article-title":"Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2","volume":"42","author":"Baser","year":"2005","journal-title":"J Med Genet"},{"key":"10.1002\/lary.25976-BIB0014|lary25976-cit-0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00129492-200409000-00027","article-title":"Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects","volume":"25","author":"Slattery","year":"2004","journal-title":"Otol Neurotol"},{"key":"10.1002\/lary.25976-BIB0015|lary25976-cit-0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","article-title":"Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity","volume":"52","author":"Parry","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1002\/lary.25976-BIB0016|lary25976-cit-0016","first-page":"918","article-title":"Mass screening for retrocochlear disorders: low-field-strength (0.2-T) versus high-field-strength (1.5-T) MR imaging","volume":"23","author":"Dubrulle","year":"2002","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1002\/lary.25976-BIB0017|lary25976-cit-0017","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1002\/lary.25976-BIB0018|lary25976-cit-0018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flary.25976","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/lary.25976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T13:24:54Z","timestamp":1533561894000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/lary.25976"}},"subtitle":["Volumetric Follow-up in Neurofibromatosis 2"],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/lary.25976","archive":["Portico"],"relation":{},"ISSN":["0023-852X"],"issn-type":[{"value":"0023-852X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,14]]}}}